Skip to content

On this page

Anthim

obiltoxaximab

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Anthim

Proper name

obiltoxaximab

Licence type

351(a)

BLA number

125509

Applicant

Elusys Therapeutics, Inc.

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
600MG/6ML (100MG/ML)	Injection	Intravenous	Single-Dose Vial	Rx	March 18, 2016

Exclusivity

Source: Purple Book

Kind	Expires
Orphan exclusivity	March 18, 2023

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity